Canexis receives extended GMP manufacturing authorization – expansion to full-service provider
Canexis Pharma has received an extended GMP manufacturing license (Part I) from Swissmedic for the production of bulk finished medicinal products. This means that Canexis is now able to manufacture not only active ingredients such as cannabidiol (CBD) and dronabinol (THC), but also standardized drug bases for pharmacy formulations and for the development of finished medicinal products – in compliance with the strictest pharmaceutical standards. With this expansion […]